"Perindopril" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An angiotensin-converting enzyme inhibitor. It is used in patients with hypertension and heart failure.
Descriptor ID |
D020913
|
MeSH Number(s) |
D03.633.100.473.766
|
Concept/Terms |
S-9490- S-9490
- S 9490
- S9490
- S 9490-3
- S 9490 3
- S 94903
|
Below are MeSH descriptors whose meaning is more general than "Perindopril".
Below are MeSH descriptors whose meaning is more specific than "Perindopril".
This graph shows the total number of publications written about "Perindopril" by people in this website by year, and whether "Perindopril" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2012 | 1 | 0 | 1 |
2016 | 1 | 0 | 1 |
2017 | 2 | 0 | 2 |
2018 | 3 | 0 | 3 |
2019 | 4 | 0 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Perindopril" by people in Profiles.
-
Feasibility of 24-h central blood pressure monitoring: experience from multinational clinical trial assessing the efficacy of perindopril/indapamide/amlodipine. J Hypertens. 2019 12; 37(12):2442-2451.
-
Evaluation of Clinical Acceptability of Perindopril / Indapamide Single-pill Combination in Moderate to Severe Hypertension. J Assoc Physicians India. 2019 Sep; 67(9):65-68.
-
Comparison of Dual Therapies for Lowering Blood Pressure in Black Africans. N Engl J Med. 2019 06 20; 380(25):2429-2439.
-
Acute Increases in Serum Creatinine After Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes Mellitus. Hypertension. 2019 01; 73(1):84-91.
-
Perindopril 3.5 mg/amlodipine 2.5 mg versus renin-angiotensin system inhibitor monotherapy as first-line treatment in hypertension: a combined analysis. J Hypertens. 2018 09; 36(9):1915-1920.
-
Rationale and design of the comparison of 3 combination therapies in lowering blood pressure in black Africans (CREOLE study): 2 × 3 factorial randomized single-blind multicenter trial. Am Heart J. 2018 08; 202:5-12.
-
Modifications in drug adherence after switch to fixed-dose combination of perindopril/amlodipine in clinical practice. Results of a large-scale Italian experience. The amlodipine-perindopril in real settings (AMPERES) study. Curr Med Res Opin. 2018 09; 34(9):1571-1577.
-
Blood pressure-lowering efficacy and safety of perindopril/indapamide/amlodipine single-pill combination in patients with uncontrolled essential hypertension: a multicenter, randomized, double-blind, controlled trial. J Hypertens. 2017 07; 35(7):1481-1495.
-
Fixed-Dose Triple Combination of Antihypertensive Drugs Improves Blood Pressure Control: From Clinical Trials to Clinical Practice. Adv Ther. 2017 04; 34(4):975-985.
-
Efficacy and Safety Assessment of Hypertension Management with Coveram (Perindopril/Amlodipine Fixed Combination) in Patients with Previous Angiotensin Receptor Blocker (ARB) Treatment: Arabian Gulf STRONG Study. Curr Vasc Pharmacol. 2016; 14(6):570-575.